Facility births are increasing globally, yet birthing environments in many low-income settings remain contaminated with bacterial pathogens that can cause serious neonatal and maternal infections, including antibiotic-resistant organisms. The CLEAN (ChLorine to reduce Enteric and Antibiotic resistant infections in Neonates) trial was designed to address this gap by evaluating whether a multi-component chlorination intervention can reduce environmental contamination and infection risk among facility-born neonates and their mothers in western Kenya.
CLEAN is a cluster randomized controlled trial conducted in western Kenya. The design tests an environmental intervention at the facility level, with medium-sized public health facilities serving as clusters. The aim is to measure both microbiological and clinical outcomes related to neonatal and maternal infection within the first month after birth.
Thirty-six medium-sized public health facilities will be randomized in a 1:1 allocation ratio. Facilities randomized to the intervention will receive the multi-component chlorination package; control facilities will continue with standard practices (status quo). The cluster design aligns the unit of randomization with the facility-level intervention to limit contamination across study arms.
The intervention combines a passive chlorination technology for treating the facility water supply with a reliable supply of chlorine-based disinfectant for cleaning and hygiene. The passive chlorinator is implemented inline with water supply systems; the trial pairs this technology with provision of chlorine-based disinfectants to support surface and hand hygiene practices. Details on the specific passive chlorination device and exact implementation procedures were described in the protocol; two investigators have organizational ties to a non-profit that partners to distribute the TuriTap chlorinator and provide in-line chlorination support, disclosed as competing interests.
Up to 22,500 mother–neonate dyads will be enrolled at birth and followed through 28 days postpartum. Enrollment focuses on facility-born neonates and their mothers to capture outcomes attributable to the facility environment and infection prevention practices during and immediately after delivery.
The protocol specifies three primary objectives: (1) to evaluate rectal carriage of sepsis-associated bacterial pathogens one week after birth among facility-born neonates and their mothers; (2) to measure the cumulative incidence of possible serious bacterial infection among neonates during the first 7 days post-birth; and (3) to measure the cumulative incidence of symptoms consistent with possible maternal sepsis in the first 7 days post-birth. The study will also capture mortality and additional infection-related measures through the 28-day follow-up period.
A subset of enrolled mother–neonate dyads will be selected for rectal swab collection to assess colonization with sepsis-associated bacterial species. In parallel, environmental samples will be collected to quantify bacterial pathogens on staff hands, high-touch surfaces, and within the water supply. These microbiological measurements are intended to link environmental contamination to colonization and clinical infection outcomes.
Participants will be followed from birth through 28 days for symptoms of infection and mortality surveillance. The primary clinical endpoints focus on the first 7 days post-birth to capture early-onset infections related to the facility environment. Microbiological sampling points include one-week post-birth rectal swabs for the subset and environmental sampling at facilities to assess changes in contamination associated with the intervention.
The study obtained ethical approval from the University of California, Berkeley and the Kenya Medical Research Institute (SERU #5188). Institutional approval was provided by the University of Minnesota through an IRB reliance agreement with UC Berkeley. Memoranda of understanding with county governments were secured and licensing obtained from the National Commission for Science Technology and Innovation. Voluntary, informed consent is obtained from adult and mature minor participants, and parental permission is obtained for neonates. The trial is registered at ClinicalTrials.gov (NCT06824350), registered 7 February 2025 as reported in the protocol.
Declared funders include the National Institutes of Health (R01AI184756), Coefficient Giving, and Global Innovation Fund. Two authors are co-founders and board members of a non-profit organization that partners to sell and distribute the TuriTap chlorinator and provide in-line chlorination technical assistance; this relationship is declared as a competing interest. All other authors reported no competing interests.
CLEAN will provide evidence on whether a combined water-supply passive chlorination intervention and chlorine disinfectant supply can reduce healthcare-associated environmental contamination, rectal colonization with sepsis-associated bacteria, and early maternal and neonatal infection outcomes in a low-resource, facility-based setting. The protocol frames the study as a means to inform scalable strategies to improve maternal and neonatal survival where facility infrastructure and infection prevention resources are limited.